MyFinsight

HomeAboutContact
Curious boy with magnifying glass
A worm made of letters APL
A worm made of letters BOA

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2024 MyFinsight. All rights reserved.

BIOREGENX, INC. (BRGX)

For the quarter ending 2025-06-30, BRGX made $445,970 in revenue. -$185,542 in net income. Net profit margin of -41.60%.

Overview

Revenue
$445,970
Net Income
-$185,542
Net Profit Margin
-41.60%
Unit: Dollar
Revenue Breakdown
    • Net sales

Unit: Dollar
2025-06-30
2025-03-31
2024-09-30
2024-06-30
Medical testing- 48,533 [1]- -
Nutritional- 467,531 [1]- -
Other sales- 416 [1]- -
Wellness devices- 10 [1]- -
Customers and direct sales- 264,874 [2]- -
Medical and academic- 167,688 [2]- -
Reseller- 83,928 [2]- -
Net sales445,970 515,147 596,037 734,032
Cost of sales93,514 109,116 114,389 264,154
Gross profit352,456 406,031 481,648 469,878
Distributors incentives- - - 112,588
Amortization expense- - 562,089 562,089
Selling, general and administrative (including equity compensation granted to officers, directors and contractors of 173,106 in the period ended june 30, 2025 and 2,512,706 in the period ended june 30, 2024)456,728 590,368 236,279 834,998
Distributors incentives2,987 8,278 10,587 -
Total operating expenses459,715 598,646 808,955 1,509,675
Loss from operations-107,259 -192,615 -327,307 -1,039,797
Interest expense and financing costs (including related party interest of 35,455 in the six months ended in june 30, 2025 and 31,063 in june 30, 202471,086 - - -
Interest expense and financing costs (including related party interest of 35,455 in the three months ended in march 31, 2025 and 31,063 in march 31, 2024- 74,239 67,553 66,331
Nonoperating income (expense)- - -67,553 -66,331
Net loss-178,345 -266,854 -394,860 -1,106,128
Foreign currency translation adjustment-7,197 -2,059 -2,561 518
Other comprehensive loss-185,542 -268,913 -397,421 -1,105,610
Loss per share - basic- - - -
Loss per share - diluted- - - -
Weighted average common shares outstanding - basic959,205,422 956,994,100 956,530,100 956,530,100
Weighted average common shares outstanding - diluted959,205,422 956,994,100 956,530,100 956,530,100
Unit: Dollar

Income Statement

DownloadDownload image
Medical Testing$87,116 Nutritional$354,263 Other Sales$237 Wellness Devices$5,168 Other comprehensiveloss-$185,542 (83.22%↑ Y/Y)Gross sales$446,784 Net loss-$178,345 (83.88%↑ Y/Y)Foreign currencytranslation adjustment-$7,197 (-1489.38%↓ Y/Y)Net sales$445,970 (-39.24%↓ Y/Y)Returns (includingcommon stock and...$814 Interest expense andfinancing costs...$71,086 Loss from operations-$107,259 (89.68%↑ Y/Y)Gross profit$352,456 (-24.99%↓ Y/Y)Cost of sales$93,514 (-64.60%↓ Y/Y)Total operatingexpenses$459,715 (-69.55%↓ Y/Y)Distributors incentives$2,987 Selling, general andadministrative (including...$456,728 (-45.30%↓ Y/Y)